

Supplementary Table 3: Neutralising antibody activity (NAb) to WT SARS-CoV-2 virus and presence or absence of SARS-CoV-2 specific T cells (SsT cells) in evaluable haematological patients (n = 19/20 evaluable) and patients with solid tumours, n=81/92 evaluable.

Haematological malignancies	CD4+ SsT cells Present	CD4+ SsT cells Absent	CD8+ SsT cells Present	CD8+ SsT cells Absent
NAb +	9 [69%]	4 [31%]	7 [54%]	6 [46%]
NAb -	2 [33%]	4 [67%]	2 [33%]	4 [67%]
Solid malignancies	CD4+ SsT cells Present	CD4+ SsT cells Absent	CD8+ SsT cells Present	CD8+ SsT cells Absent
NAb +	58 [84%]	11 [16%]	39 [57%]	30 [43%]
NAb -	8 [67%]	4 [33%]	2 [17%]	10 [83%]

NAb +, neutralising antibodies positive; NAb-, neutralising antibodies negative.